Brett Zbar to lead life sci­ences in­vest­ing at Gen­er­al At­lantic; Michael Ka­vanaugh plans re­tire­ment as Cy­tomX pro­motes Genen­tech vet Mar­cia Belvin

→ Growth eq­ui­ty firm Gen­er­al At­lantic has reeled in Brett Zbar as man­ag­ing di­rec­tor to lead its new life sci­ences fo­cus. Zbar hops aboard from Fore­site Cap­i­tal where he served as man­ag­ing di­rec­tor and ad­vised on the boards of com­pa­nies such as Kin­nate Bio­phar­ma, ORIC Phar­ma­ceu­ti­cals and Sig­nant Health among oth­ers. Pri­or to his role at Fore­site, Zbar was a part­ner at Ais­ling Cap­i­tal.

Michael Ka­vanaugh has an­nounced his re­tire­ment ef­fec­tive Dec. 1 as CSO, head of re­search and non-clin­i­cal de­vel­op­ment of Cy­tomX. Ac­cord­ing to the re­lease, he’s tran­si­tion­ing to an ad­vi­so­ry role. Ka­vanaugh had been with the on­col­o­gy biotech since 2015 af­ter hold­ing the same ti­tles at Five Prime Ther­a­peu­tics. VP of on­col­o­gy re­search Mar­cia Belvin, who came to Cy­tomX 2 years ago, has been pro­mot­ed to SVP, head of re­search. Belvin pre­vi­ous­ly held mul­ti­ple po­si­tions lead­ing can­cer pro­grams and pre­clin­i­cal pipeline teams dur­ing 13 years at Genen­tech and got her start at Ex­elix­is.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.